A report on the research and activist work that led to the federal government taking nearly unprecedented action against the pharmaceutical company.
After finally being connected to care, health activist Mason runs into more obstacles -- and another unexpected wait for lifesaving medication.
Poverty, stigma and racial health disparities drive HIV rates that are among the nation's highest. But expanded Medicaid and PrEP access seem to have contributed to a recent drop in new cases.
As the 2020 presidential hopeful touts her HIV activist record, doubts remain as to whether her version of events is the full truth.
In North Carolina, Greater Charlotte is booming, but income disparity, Immigration and Customs Enforcement (ICE) raids on immigrants, and spread-out service providers all create challenges to reversing HIV rates.
Why do Americans and their insurers pay more for some drugs and less for others? And who decides what a fair price for a drug should be, and how can manufacturers and health plans be compelled to improve access and affordability?
First, they were diagnosed. Then, they started treatment. Then, they advocated for others. In this roundtable, three treatment activists discuss their journeys.
From protesting "big pharma" about the cost of meds, to being on meds himself, Marco Benjamin's journey with starting treatment is nuanced, and the subject of this op-ed.
The pharmaceutical industry just doesn't get it. Here we are on the cusp of a revolution in medicine, with genomic insights likely to yield a generation of medicinal products safer and more effective than any before; with burgeoning markets, record p...